癌症与白血病B组140503(Alliance)试验中T1aN0非小细胞肺癌肺叶与亚肺叶切除术后第二原发肺癌率的二次分析
该研究为多中心、国际、随机、III期试验的二次分析,纳入T1aN0非小细胞肺癌患者,比较亚肺叶切除(SLR)与肺叶切除(LR)后第二原发肺癌(SPLC)的发生率。中位随访7年,研究总体、SLR组和LR组SPLC年发生率分别为3.4%、3.8%和3.1%,5年累积发生率分别为15.9%、17.2%和14.7%。
要点
- 研究总体SPLC年发生率为3.4%(95%CI 2.9-4.1),5年累积发生率为15.9%(95%CI 12.9-18.9)。
- SLR组SPLC年发生率为3.8%(95%CI 2.9-4.9),5年累积发生率为17.2%(95%CI 12.7-21.5)。
- LR组SPLC年发生率为3.1%(95%CI 2.4-4.1),5年累积发生率为14.7%(95%CI 10.6-18.7)。
核心结论
- 在T1aN0非小细胞肺癌患者中,亚肺叶切除与肺叶切除术后第二原发肺癌的年发生率和5年累积发生率数值上SLR组略高于LR组,但原文未报告组间比较的统计学检验结果。
研究设计与样本
- 癌症与白血病B组140503(Alliance)为多中心、国际、随机、III期试验,纳入T1aN0非小细胞肺癌患者(采用第七版TNM分期系统),比较亚肺叶切除与肺叶切除。
- 本次分析为二次分析,评估研究总体及SLR组和LR组的SPLC年发生率(每患者每年)和5年累积发生率,中位随访7年。
主要发现
- 研究总体SPLC年发生率为3.4%(95%CI 2.9-4.1),SLR组为3.8%(95%CI 2.9-4.9),LR组为3.1%(95%CI 2.4-4.1)。
- 研究总体SPLC 5年累积发生率为15.9%(95%CI 12.9-18.9),SLR组为17.2%(95%CI 12.7-21.5),LR组为14.7%(95%CI 10.6-18.7)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Patients with early-stage non-small-cell lung cancer (NSCLC) who undergo curative surgical resection are at risk for developing second primary lung cancer (SPLC). Cancer and Leukemia Group B 140503 (Alliance) was a multicenter, international, randomized, phase III trial in patients with stage T1aN0 NSCLC (using the TNM staging system seventh edition) and demonstrated the noninferiority for disease-free survival between sublobar resection (SLR) and lobar resection (LR). After surgery, patients underwent computed tomography surveillance as defined by the protocol. The determination of a SPLC was done by the treating physician and recorded in the study database. We performed an analysis of the rate of SPLC (per patient per year) and the 5-year cumulative incidence in the study population and within the SLR and LR arms. Median follow-up was 7 years. The rate per patient per year in the study population, in the SLR arm, and in the LR arm was 3.4% (95% CI, 2.9 to 4.1), 3.8% (95% CI, 2.9 to 4.9), and 3.1% (95% CI, 2.4 to 4.1), respectively. The estimated 5-year cumulative incidence of SPLC in the study population, SLR arm, and LR arm was 15.9% (95% CI, 12.9 to 18.9), 17.2% (95% CI, 12.7 to 21.5), and 14.7% (95% CI, 10.6 to 18.7), respectively.
引用
- Stinchcombe TE, Wang X, Damman B, et al. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024. PMID: 38215351. doi:10.1200/JCO.23.01306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。